Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post–Program Implementation: Observational Case–Control Study

4CMenB demonstrates moderate effectiveness against gonococcal infection, with a lower VE estimate after 4 years postvaccination. 4CMenB may reduce the risk of recurrent gonococcal infection. The requirement for a booster dose and dosing interval warrants evaluation.